AU673153B2 - A method for estimating the biologic potential of a selected carcinoma in a patient - Google Patents
A method for estimating the biologic potential of a selected carcinoma in a patient Download PDFInfo
- Publication number
- AU673153B2 AU673153B2 AU34782/93A AU3478293A AU673153B2 AU 673153 B2 AU673153 B2 AU 673153B2 AU 34782/93 A AU34782/93 A AU 34782/93A AU 3478293 A AU3478293 A AU 3478293A AU 673153 B2 AU673153 B2 AU 673153B2
- Authority
- AU
- Australia
- Prior art keywords
- carcinoma
- carcinomas
- prostate
- estimating
- vascularity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
- G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
- Y10S436/813—Cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analyzing Materials By The Use Of Electric Means (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
Abstract
A method for estimating the biologic potential of prostate carcinoma in a patient is disclosed, comprising the steps of (a) obtaining a limited random biopsy sample of prostate carcinoma from a patient, and (b) quantifying the vascularity of the biopsy, and therefrom estimating the metastatic potential of the prostate carcinoma. Also disclosed is a method for estimating the biologic potential of a selected carcinoma in a patient, comprising the steps of (a) obtaining a limited random biopsy specimen from a carcinoma by a method selected from the group consisting of needle biopsy, endoscopy, laproscopy, and cystoscopy, and (b) quantifying the vascularity of the biopsy specimen, and therefrom estimating biologic potential of the selected carcinoma.
Description
I r OPI DATE 03/08/93 APPLN. ID 34782/93 AOJP DATE 14/10/93 PCT NUMBER PCT/US93/00449 AU9334782 1
J
I
[j A. LrtiTY (PCT) (51) International Patent Classification 5 (l1) international Publication Number: WO 93/14407 G01N 33/574, 33/48 A l (43) International Publication Date: 22 July 1993 (22.07.93) (21) International Application Number: PCT/US93/00449 Published With international search report.
(22) International Filing Date: 15 January 1993 (15.01.93) Priority data: 07/821,120 15 January 1992 (15.01.92) US I6 7 f Appli*eknd Inventor: BRAWER, Michael, K. [US/ US]; 8158 West Mercer Way, Mercer Island, WA 98040
(US).
(74) Agents: MAKI, David, J. et al.; Seed and Berry, 6300 Columbia Center, 701 Fifth Avenue, Seattle, WA 98104-7092 (US).
(81) Designated States: AU, BR, CA, FI, JP, NO, European pa- r'T tent (AT, BE, CH. DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
(54)Title: A METHOD FOR ESTIMATING THE BIOLOGIC POTENTIAL OF A SELECTED CARCINOMA IN A PA-
TIENT
(57) Abstract A method for estimating the biologic potential of prostate carcinoma in a patient is provided, comprising the steps of (a) obtaining a tissue sample of prostate carcinoma from a patient, and quantifying the vascularity of the tissue sample, and therefrom estimating the biologic potential of the prostate carcinoma. Also provided is a method for estimating the biologic potential of a selected carcinoma in a patient, comprising the steps of obtaining a biopsy specimen from a carcinoma by a method selected from the group consisting of needle biopsy, endoscopy, laproscopy, and cystoscopy, and quantifying the vascularity of the biopsy specimen, and therefrom estimating biologic potential of the selected carcinoma.
i If ib i I S! i: I r I
Claims (13)
1. A method for estimating the carcinoma in a patient, comprising: quantifying the vascularity of a tissue obtained from a patient, and therefrom estimating prostate carcinoma. biologic potential of prostate sample of prostate carcinoma the biologic potential of said
2. A method according to claim 1 wherein said tissue sample is composed of one or more needle biopsy specimens.
3. A method according to claim 1 wherein said tissue sample is composed of one or more tissue sections of prostate carcinoma obtained by transurethral resection of the prostate.
4. A method according to claim 1 wherein said tissue sample is composed of one or more tissue sections of prostate carcinoma obtained by transurethral biopsy of the prostate.
A method according to claim 1 wherein said tissue sample is composed of one or more tissue sections of prostate carcinoma obtained by partial or complete surgical excision of the prostate.
6. A method according to claim 1 wherein said step of quantifying vascularity comprises manual morphometric quantification of vascular components in the tissue sample.
7. A method according to claim 1 wherein said step of quantifying vascularity comprises computer-aided morphometric quantification of vascular components in the tissue sample.
8. A method according to claim 1 wherein said tissue sample is composed of one or more carcinomatous tissue fragments of the prostate obtained by needle biopsy, transurethral resection, or surgical excision. 7 7 -28
9. A method for estimating the biologic potential of a selected carcinoma in a patient, comprising: obtaining a tissue specimen from a carcinoma in vivo by a method selected from the group consisting of needle biopsy, endoscopy, laproscopy, and cystoscopy; and quantifying the vascularity of said biopsy specimen, and therefrom estimating biologic potential of the selected carcinoma.
A method according to claim 9 wherein said step of quantifying vascularity comprises manual morphometric quantification of vascular components in the biopsy specimen.
11. A method according to claim 9 wherein said step of quantifying i vascularity comprises computer-aided morphometric quantification of vascular components in the biopsy specimen.
12. A method according to claim 9 wherein the carcinoma is selected from a group consisting of head and neck tumors, CNS tumors, melanomas and other skin tumors, lymphomas, soft tissue sarcomas, breast carcinomas, bladder carcinomas, pancreatic carcinomas, colon carcinomas, urothelial carcinomas, testicular carcinomas, :cervical carcinomas, uterine carcinomas, renal carcinomas, ovarian carcinomas, hepatic carcinomas, pulmonary carcinomas, esophageal carcinomas, and gastric carcinomas.
13. A method for estimating the biologic potential of a selected carcinoma in a patient comprising: obtaining a limited random biopsy sampling of a carcinoma; and quantifying the vascularity of said biopsy sampling, and therefrom estimating the biologic potential of the selected carcinoma. DATED this 15th day of November, 1995 Michael K BRAWER By His Patent Attorneys DAVIES COLLISON CAVE IV 1 9511 15,qAoper\ejh,34782.319,28 vaclrtAomrsscmutraddTrpoercqaniiainofvsua
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82112092A | 1992-01-15 | 1992-01-15 | |
| US821120 | 1992-01-15 | ||
| PCT/US1993/000449 WO1993014407A1 (en) | 1992-01-15 | 1993-01-15 | A method for estimating the biologic potential of a selected carcinoma in a patient |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU3478293A AU3478293A (en) | 1993-08-03 |
| AU673153B2 true AU673153B2 (en) | 1996-10-31 |
Family
ID=25232578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU34782/93A Ceased AU673153B2 (en) | 1992-01-15 | 1993-01-15 | A method for estimating the biologic potential of a selected carcinoma in a patient |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US5688694A (en) |
| EP (1) | EP0643839B1 (en) |
| JP (1) | JPH07503069A (en) |
| AT (1) | ATE145728T1 (en) |
| AU (1) | AU673153B2 (en) |
| CA (1) | CA2128031A1 (en) |
| DE (1) | DE69306250T2 (en) |
| ES (1) | ES2095038T3 (en) |
| FI (1) | FI943355A7 (en) |
| NO (1) | NO942653L (en) |
| WO (1) | WO1993014407A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1158047B1 (en) * | 1999-03-05 | 2009-05-20 | Mitsubishi Rayon Co., Ltd. | Microarrays having biological substance |
| JP2003520830A (en) | 2000-01-25 | 2003-07-08 | エドワーズ ライフサイエンシーズ コーポレイション | Delivery system for treatment of restenosis and anastomotic intimal hyperplasia |
| AU1782102A (en) | 2000-11-06 | 2002-05-15 | Univ Texas | Laser scanning cytometry mediated analysis of therapeutic efficacy in tumors |
| US6993175B2 (en) * | 2001-09-07 | 2006-01-31 | Quest Diagnostics Investments Incorporated | Methods for measuring microvascular density in tumors |
| US7229423B2 (en) * | 2003-02-05 | 2007-06-12 | Timi 3 System, Inc | Systems and methods for applying audible acoustic energy to increase tissue perfusion and/or vasodilation |
| US20070100335A1 (en) * | 2005-10-28 | 2007-05-03 | Apple Medical Corporation | Instrument for electrosurgical excision procedure for the uterine cervix |
| WO2011028146A1 (en) * | 2009-09-04 | 2011-03-10 | Korotkov Konstantin Georgievich | Method for determining the condition of a biological object and device for making same |
| FR2964744B1 (en) * | 2010-09-10 | 2015-04-03 | Univ Versailles St Quentin En Yvelines | PROGNOSTIC TEST OF THE EVOLUTION OF A SOLID TUMOR BY ANALYSIS OF IMAGES |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU8950291A (en) * | 1990-10-16 | 1992-05-20 | Biomedical Frontiers, Inc. | Polymer-deferoxamine-ferric iron adducts for use in magnetic resonance imaging |
-
1993
- 1993-01-15 AU AU34782/93A patent/AU673153B2/en not_active Ceased
- 1993-01-15 EP EP93903564A patent/EP0643839B1/en not_active Expired - Lifetime
- 1993-01-15 DE DE69306250T patent/DE69306250T2/en not_active Expired - Fee Related
- 1993-01-15 JP JP5512702A patent/JPH07503069A/en active Pending
- 1993-01-15 FI FI943355A patent/FI943355A7/en not_active Application Discontinuation
- 1993-01-15 ES ES93903564T patent/ES2095038T3/en not_active Expired - Lifetime
- 1993-01-15 CA CA002128031A patent/CA2128031A1/en not_active Abandoned
- 1993-01-15 AT AT93903564T patent/ATE145728T1/en not_active IP Right Cessation
- 1993-01-15 WO PCT/US1993/000449 patent/WO1993014407A1/en not_active Ceased
-
1994
- 1994-07-14 NO NO942653A patent/NO942653L/en unknown
- 1994-12-07 US US08/351,724 patent/US5688694A/en not_active Expired - Fee Related
-
1995
- 1995-06-05 US US08/462,791 patent/US5616469A/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU8950291A (en) * | 1990-10-16 | 1992-05-20 | Biomedical Frontiers, Inc. | Polymer-deferoxamine-ferric iron adducts for use in magnetic resonance imaging |
Non-Patent Citations (1)
| Title |
|---|
| TAKANO ET AL: BRAIN AND NERVE 43 PP145-152 1991 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0643839A1 (en) | 1995-03-22 |
| FI943355A0 (en) | 1994-07-14 |
| WO1993014407A1 (en) | 1993-07-22 |
| EP0643839B1 (en) | 1996-11-27 |
| NO942653L (en) | 1994-09-12 |
| DE69306250T2 (en) | 1997-03-20 |
| US5616469A (en) | 1997-04-01 |
| DE69306250D1 (en) | 1997-01-09 |
| JPH07503069A (en) | 1995-03-30 |
| US5688694A (en) | 1997-11-18 |
| NO942653D0 (en) | 1994-07-14 |
| FI943355L (en) | 1994-09-14 |
| AU3478293A (en) | 1993-08-03 |
| ES2095038T3 (en) | 1997-02-01 |
| FI943355A7 (en) | 1994-09-14 |
| ATE145728T1 (en) | 1996-12-15 |
| CA2128031A1 (en) | 1993-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rosen et al. | Discontinuous or" skip" metastases in breast carcinoma. Analysis of 1228 axillary dissections | |
| Evan et al. | Crystal-associated nephropathy in patients with brushite nephrolithiasis | |
| US7794926B2 (en) | Detection of survivin in the biological fluids of cancer patients | |
| AU673153B2 (en) | A method for estimating the biologic potential of a selected carcinoma in a patient | |
| Lee | Mucins in Barrett’s esophagus: a histochemical study | |
| Gaudin et al. | Incidence and clinical significance of high-grade prostatic intraepithelial neoplasia in TURP specimens | |
| Paraskevaidis et al. | A population-based study of microinvasive disease of the cervix—a colposcopic and cytologic analysis | |
| Scaletscky et al. | Tumor volume and stage in carcinoma of the prostate detected by elevations in prostate specific antigen | |
| Kingston et al. | Role of frozen section and clinical parameters in distinguishing benign from malignant follicular neoplasms of the thyroid | |
| Barrett et al. | An immunohistological study of cytokeratin 20 in human and mammalian oral epithelium | |
| Miwa et al. | Rationale for extensive lymphadenectomy in early gastric carcinoma | |
| Sano et al. | The management of early gastric cancer | |
| Andrews et al. | Therapeutic implications of lymph nodal spread in lateral T1 and T2 squamous cell carcinoma of the vulva | |
| Oohara et al. | Clinical diagnosis of minute gastric cancer less than 5 mm in diameter | |
| Yura et al. | Parametrial involvement in endometrial carcinomas: its incidence and correlation with other histological parameters | |
| Humphrey et al. | Adenocarcinoma of the prostate: Part II: Tissue prognosticators | |
| Cooper et al. | Random mucosal biopsies in the evaluation of patients with carcinoma of the bladder | |
| Itsukaichi et al. | Stage Ia1 cervical squamous cell carcinoma: conservative management after laser conization with positive margins | |
| Hagen et al. | CO 2 laser conization for cervical intraepithelial neoplasia grade II-III, complications and efficacy | |
| Mori et al. | Clinicopathologic studies of gastric carcinoma | |
| Kurita et al. | Transition zone volume-adjusted prostate-specific antigen value predicts extracapsular carcinoma of the prostate in patients with intermediate prostate-specific antigen levels | |
| St. Louis et al. | Follicular neoplasms: the role for observation, fine needle aspiration biopsy, thyroid suppression, and surgery | |
| Sacker et al. | Primary osteosarcoma of the penis | |
| Hall et al. | The use of the red cell surface antigen to predict the malignant potential of transitional cell carcinoma of the ureter and renal pelvis | |
| Gilchrist et al. | Pleomorphic microvilli and low-grade human urothelial cancer Need to correlate diagnostic modalities |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |